About this Research Topic
Recent advances have unraveled molecular and cellular mechanisms regulating the interaction between microenvironmental components and tumor epithelia leading to a new era of personalized therapies. The approvals of a variety of immunotherapies including anti-PD1/PD-L1 highlight the promise of further understanding these mechanisms. Despite these developments, such therapies have shown limited applicability in tumors of the gastrointestinal tract. For instance, immunotherapies such as anti-PD1 are only effective in a small portion of colorectal cancers with high microsatellite instability. This exemplifies the pressing need to better understand molecular and cellular factors influencing the tumor microenvironment and consequently the response to therapy.
Declarations:
1. NW is a patent holder for a DCLK1 monoclonal antibody US9663585B2
2. DQ is a patent holder for a DCLK1 monoclonal antibody US9663585B2
Declarations:
1. NW is a patent holder for a DCLK1 monoclonal antibody US9663585B2
2. DQ is a patent holder for a DCLK1 monoclonal antibody US9663585B2
Keywords: Cancer stem cells, Cell-of-origin, Patient-derived organoids, Tumor microenvironment, Personalized medicine, Biomarkers, Novel Molecular Targets
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
